Unicycive Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Significant Agreements (Details)

Significant Agreements (Details) - USD ($) $ in Thousands									1 Months Ended				3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
Significant Agreements (Details) - USD ($) $ in Thousands	Apr. 10, 2023	Feb. 28, 2023	Feb. 01, 2023	Aug. 31, 2022	Jul. 14, 2022	Feb. 09, 2022	Jan. 06, 2022	Jul. 13, 2021	Mar. 31, 2023	Jul. 19, 2021	Sep. 30, 2018	Oct. 30, 2017	Mar. 31, 2023	Jun. 30, 2023	Sep. 30, 2021	Dec. 31, 2022
Significant Agreements (Details) [Line Items]
Company agreement description														According to the terms of the agreement Unicycive will pay the vendor $2 million in the first calendar year when the net revenue reaches $10 million from sales of Oxylanthanum Carbonate following its approval by the FDA and commercial supply of the product by the vendor (First Payment). Thereafter, the Company will pay $2 million per year for four consecutive years, after the first year’s payment, for the total payments of $10 million, provided all commercial supplies are continued to be manufactured and supplied by the vendor.
Agreement payments														$ 2,000
License agreement, description												No payments were made upon execution of the agreement but rather payments for $50,000 will be due commencing with the initiation by the Company of a second clinical trial and $50,000 on completion of such trial. At the time the FDA accepts a NDA application submitted by the Company for the product, the Company will pay Sphaera $1.65 million. Upon commercialization and sale of the drug product, royalty payments will also be payable quarterly to Sphaera equal to 2% of net sales on the preceding quarter.
Common stock valued
Public market capitalization								$ 50,000
Anti-dilution shares of common stock (in Shares)								438,374
Research and development expenses	$ 1,300														$ 2,200
Sublicense income percentage														40.00%
Upfront payment amount				$ 1,000
Spectrum agreement percentage																20.00%
Related payments														$ 2,200
Revisions reduced overall budget							$ 3,100
Prepaid expenses														1,000
Remaining services budget									$ 100				$ 100
Agreements payment														1,400
Tiered royalties percentage					10.00%
Received upfront payment			$ 700
Future milestone payments			$ 3,700
Agreements [Member]
Significant Agreements (Details) [Line Items]
Agreement payments														$ 1,000
Syneos Health LLC [Member]
Significant Agreements (Details) [Line Items]
Sublicense income percentage														20.00%
Research related payments		$ 700
Quotient Sciences Limited [Member]
Significant Agreements (Details) [Line Items]
Research related payments														$ 2,200
Prepaid expenses														1,200
Spectrum Pharmaceuticals, Inc. [Member]
Significant Agreements (Details) [Line Items]
Company issued shares (in Shares)											313,663
Common stock valued											$ 4,000
Market capitalization											$ 50,000
Spectrum Pharmaceuticals, Inc. [Member] \| Investment [Member]
Significant Agreements (Details) [Line Items]
Interest on ownership											4.00%
Altair Nanomaterials, Inc [Member]
Significant Agreements (Details) [Line Items]
Required to pay															200
Altair [Member]
Significant Agreements (Details) [Line Items]
Required to pay															$ 4,500
Oxylanthanum Carbonate [Member]
Significant Agreements (Details) [Line Items]
Research and development expenses														$ 1,300
Sublicense income percentage														20.00%
Research related payments														$ 2,700
Prepaid expenses														$ 2,700
Syneos Health LLC [Member]
Significant Agreements (Details) [Line Items]
Research and development expenses										$ 2,300
Quotient Sciences Limited [Member]
Significant Agreements (Details) [Line Items]
Research and development expenses							$ 3,700
CBCC Global Research Inc [Member]
Significant Agreements (Details) [Line Items]
Research and development expenses						$ 1,400
Research related payments									400
Related expense									$ 400
Lee’s Pharmaceutical (HK) Limited [Member]
Significant Agreements (Details) [Line Items]
Research and development expenses					$ 1,000
Research related payments					$ 1,000
Tiered royalties percentage					7.00%